Home Publications Research Grants Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

Pharmacological inhibition of mtorc2 reduces migration and metastasis in melanoma

Guenzle J, Akasaka H, Joechle K, Reichardt W, Venkatasamy A, Hoeppner J, Hellerbrand C, Fichtner-Feigl S, Lang SA (2021)

---

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 22

Pages Range: 1-16

Article Number: 30

Journal Issue: 1

DOI: 10.3390/ijms22010030

Abstract

Despite recent advances in therapy, liver metastasis from melanoma is still associated with poor prognosis. Although targeting the mTOR signaling pathway exerts potent anti-tumor activity, little is known about specific mTORC2 inhibition regarding liver metastasis. Using the novel mTORC2 specific inhibitor JR-AB2-011, we show significantly reduced migration and invasion capacity by-impaired activation of MMP2 in melanoma cells. In addition, blockade of mTORC2 induces cell death by non-apoptotic pathways and reduces tumor cell proliferation rate dose-dependently. Furthermore, therapy with JR-AB2-011 as determined by in vivo imaging and necropsy. Hence, our study for a significant reduction of liver metastasis was detected in a syngeneic murine metastasis model upon the first time highlights the impact of the pharmacological blockade of mTORC2 as a potent novel anti-cancer approach for liver metastasis from melanoma.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Guenzle, J., Akasaka, H., Joechle, K., Reichardt, W., Venkatasamy, A., Hoeppner, J.,... Lang, S.A. (2021). Pharmacological inhibition of mtorc2 reduces migration and metastasis in melanoma. International Journal of Molecular Sciences, 22(1), 1-16. https://dx.doi.org/10.3390/ijms22010030

MLA:

Guenzle, Jessica, et al. "Pharmacological inhibition of mtorc2 reduces migration and metastasis in melanoma." International Journal of Molecular Sciences 22.1 (2021): 1-16.

BibTeX: Download